BRIEF—Abivax names Sheldon Sloan as CMO

French clinical-stage biotech Abivax today announced the appointment of Dr Sheldon Sloan as new chief medical officer, effective on March 1, 2023.

Prior to joining Abivax, Dr Sloan worked for Arena Pharmaceuticals and, after its acquisition, for Pfizer. He was program lead for Etrasimod UC, responsible for cross-functional leadership, planning and management, operational business process planning, and execution management of the Ulcerative Colitis program, including its global submission and launch.

Dr Sloan brings over 30 years of experience in academia and the biopharmaceutical industry, with an extensive track record in the field of gastroenterology and inflammatory bowel disease (IBD).

He has spent the last 25 years of his career in large pharmaceutical and biotech companies, including 15 years in leading positions at Johnson & Johnson.